AKARX
AkaRx, Inc., a biopharmaceutical company, develops therapeutic treatments for unmet medical needs. Its product includes AKR-501, an orally-available small molecule for use in the treatment of thrombocytopenia. The company was founded in 2005 and is headquartered in Paramus, New Jersey.
AKARX
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2005-01-01
Address:
Paramus, New Jersey, United States
Country:
United States
Status:
Active
Total Funding:
21.1 M USD
Similar Organizations
Anthos Therapeutics
Anthos Therapeutics is a biopharmaceutical company that specializes in the treatment of cardiovascular and metabolic diseases.
Atterx Biotherapeutics
Atterx develops therapeutics to fight the growing epidemic of antibiotic resistant bacteria.
Resolvyx Pharmaceuticals
Resolvyx Pharmaceuticals develops therapeutics with small molecule lipid mediators for the treatment of inflammatory diseases.
Investors List
Sutter Hill Ventures
Sutter Hill Ventures investment in Series A - AkaRx
InterWest Partners
InterWest Partners investment in Series A - AkaRx
InterWest Partners
InterWest Partners investment in Series A - AkaRx
Sutter Hill Ventures
Sutter Hill Ventures investment in Series A - AkaRx
InterWest Partners
InterWest Partners investment in Series A - AkaRx
Sutter Hill Ventures
Sutter Hill Ventures investment in Series A - AkaRx
More informations about "AkaRx"
Akarx, Inc. Company Profile | Morrisville, NC - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Akarx, Inc. of Morrisville, NC. Get the latest business insights from Dun & Bradstreet.See details»
Eisai Initiates Procedures to Acquire AkaRx, Inc. in the United States
3. Year-end dividend forecast. In cash-flow, the expense that will occur in association with the acquisition of AkaRx, will be accounted as cash-flow used in investment activities and will not …See details»
AkaRx - Products, Competitors, Financials, Employees, …
AkaRx develops therapeutic products including avatrombopag, which is an investigational oral thrombopoietin receptor agonist. Use the CB Insights Platform to explore AkaRx's full profile. …See details»
Eisai Completes Acquisition of AkaRx, Inc. in the United States
As a result, all procedures to acquire AkaRx as announced by Eisai on December 18, 2009 (Japan time) have now been completed. The buyout price of this acquisition is US$255 million. …See details»
Akarx Inc · 240 Leigh Farm Rd, Ste 245, Durham, NC 27707-8100
AKARX INC is an entity in Durham, North Carolina registered with the System for Award Management (SAM) of U.S. General Services Administration (GSA). The entity was registered …See details»
Akarx, Inc. - Company Profile - Corporation Wiki
Apr 6, 2022 Akarx, Inc. Overview. Akarx, Inc. filed as a Foreign For-Profit Corporation in the State of Texas on Wednesday, April 6, 2022 and is approximately three years old, as recorded …See details»
AkaRx - Funding, Financials, Valuation & Investors - Crunchbase
AkaRx develops therapeutics including the orally-available small molecule for use in the treatment of thrombocytopenia. New. Resources. Advanced Search. ... How much funding has this …See details»
AkaRx, Inc. · 3015 Carrington Mill Boulevard, Suite 410, Morrisville ...
AkaRx, Inc. (Entity #20221595379) is a FPC in Morrisville, North Carolina registered with the Colorado Department of State (CDOS). The entity was formed on June 20, 2022 in the …See details»
AkaRx - Crunchbase
Organization. AkaRx . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. Similar Companies. Edit Similar Companies Section. AkaRx, Atterx …See details»
Eisai Completes Acquisition of AkaRx, Inc. and Continues …
Jan 6, 2010 Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as …See details»
AkaRx, Inc. - VentureRadar
Similar Companies: Ception Therapeutics USA n/a n/a. Proteostasis Therapeutics USA Publicly Traded Proteostasis Therapeutics is an innovative biopharmaceutical company committed to …See details»
AkaRx, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore AkaRx, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 1 news, and 2 literature, Disease Domain:Hemic and Lymphatic Diseases, Immune System …See details»
AkaRx, Inc. - VentureRadar
Similar Companies: Epizyme USA Listed Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and …See details»
EISAI'S U.S. SUBSIDIARY EISAI INC. ENTERS SHARE ... - Eisai Co., Ltd.
Mar 30, 2016 By transferring the shares of AkaRx to PBM, Eisai intends to focus its management resources on oncology and neurology. The impact of this transfer on Eisai's …See details»
AkaRx, Inc | VentureRadar
AkaRx, Inc VentureRadar profile. Find out more about AkaRx, Inc including the VentureRadar Innovation and Growth scores, Similar Companies and more.See details»
Eisai Completes Acquisition of AkaRx | PHARMA JAPAN
Jan 18, 2010 Eisai announced on January 7 that its US subsidiary Eisai Inc. acquired all shares of AkaRx, Inc. for US$255 million on January 6 and has made the company its wholly-owned …See details»
Eisai closes $255 million acquisition of AkaRx | Drug Store News
Jan 7, 2010 The acquisition of AkaRx marks the culmination of a development license agreement and a deferred merger agreement, both of which originally were signed between …See details»
Avatrombopag Gains FDA Approval for Patients with Chronic Liver …
May 22, 2018 The drug is expected to be made available in June, according to Dova Pharmaceuticals, the parent company of AkaRx.2 “Doptelet is the first orally administered …See details»
Avatrombopag Tablet Approved by FDA for Patients with Chronic …
May 22, 2018 The drug is expected to be made available in June, according to Dova Pharmaceuticals, the parent company of AkaRx.2 “Doptelet is the first orally administered …See details»